Arbutus Biopharma Corporation (ABUS)
Market Cap | 760.79M |
Revenue (ttm) | 10.06M |
Net Income (ttm) | -77.09M |
Shares Out | 188.78M |
EPS (ttm) | -0.44 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 943,094 |
Open | 4.060 |
Previous Close | 4.070 |
Day's Range | 3.910 - 4.075 |
52-Week Range | 1.690 - 4.720 |
Beta | 1.91 |
Analysts | Strong Buy |
Price Target | 5.25 (+30.27%) |
Earnings Date | Nov 5, 2024 |
About ABUS
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, ... [Read more]
Financial Performance
In 2023, Arbutus Biopharma's revenue was $18.14 million, a decrease of -53.51% compared to the previous year's $39.02 million. Losses were -$72.85 million, 4.89% more than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ABUS stock is "Strong Buy." The 12-month stock price forecast is $5.25, which is an increase of 30.27% from the latest price.
News
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
WARMINSTER, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive virolo...
Arbutus to Participate in Two Upcoming Investor Conferences
WARMINSTER, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virol...
Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2024 Earnings Conference Call August 1, 2024 8:45 AM ET Company Participants Lisa Caperelli - VP, Investor Relations Michael McElhaugh - Interim Preside...
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fun...
Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity
Arbutus Biopharma's three-pronged strategy targets cHBV by suppressing HBV DNA, reducing viral antigens, and boosting immune response. Imdusiran (AB-729) shows promise in Phase 2 trials, potentially l...
Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress
Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were ...
Arbutus Distributors Ltd. News Release
VANCOUVER, British Columbia, June 03, 2024 (GLOBE NEWSWIRE) -- Mr. Peter Bull and Arbutus Distributors Ltd. (“Arbutus”), a private investment and holding company controlled by Mr. Bull, announced toda...
Arbutus to Participate in Jefferies Global Healthcare Conference
WARMINSTER, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a func...
Arbutus to Present Imdusiran Data at EASL Congress 2024
WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virolog...
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
NEW YORK--(BUSINESS WIRE)--Whitefort Capital Management, LP (together with its affiliates, “Whitefort Capital,” “us” or “we”), which is a long-term investor and the second largest shareholder of Arbut...
Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Conference Call May 2, 2024 8:45 AM ET Company Participants Lisa Caperelli - Vice President, Investor Relations Mike McElhaugh - Interim P...
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virolog...
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fu...
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
WARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fu...
Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript
Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fun...
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline
Arbutus to Present at Jefferies London Healthcare Conference
WARMINSTER, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virolo...
Arbutus Biopharma Corporation (ABUS) Q3 2023 Earnings Call Transcript
Arbutus Biopharma Corporation. (NASDAQ:ABUS) Q3 2023 Earnings Conference Call November 7, 2023 9:00 AM ET Company Participants Lisa Caperelli - VP of IR Bill Collier - President, CEO and Director Dav...
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Multiple data presentations upcoming at AASLD – The Liver Meeting®, including preliminary data from Phase 2a clinical trial combining imdusiran, our RNAi therapeutic, with VTP-300, an HBV antigen-spec...